These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9814644)

  • 1. The potential impact of platelet growth factors in transfusion medicine.
    McCullough J
    Curr Opin Hematol; 1998 Nov; 5(6):386-90. PubMed ID: 9814644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet growth factors: potential impact on transfusion medicine.
    Kuter DJ; Cebon J; Harker LA; Petz LD; McCullough J
    Transfusion; 1999 Mar; 39(3):321-32. PubMed ID: 10204598
    [No Abstract]   [Full Text] [Related]  

  • 3. Thrombocytopenia after high-dose chemotherapy and autologous stem cell transplantation: an unresolved problem and possible approaches to resolve it.
    Hassan HT; Zander AR
    J Hematother; 1996 Aug; 5(4):407-14. PubMed ID: 8877716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical biology and potential use of thrombopoietin.
    Basser R
    Can J Gastroenterol; 2000 Nov; 14 Suppl D():73D-78D. PubMed ID: 11110616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietin: biology, clinical applications, role in the donor setting.
    Kuter DJ
    J Clin Apher; 1996; 11(3):149-59. PubMed ID: 8915820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
    Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
    Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietin: biology and potential clinical applications.
    Prow D; Vadhan-Raj S
    Oncology (Williston Park); 1998 Nov; 12(11):1597-604, 1607-8; discussion 1611-4. PubMed ID: 9834938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memorial lecture. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
    Hofmann WK; Ottmann OG; Hoelzer D
    Leukemia; 1999 Apr; 13 Suppl 1():S14-8. PubMed ID: 10232362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin: understanding and manipulating platelet production.
    Kaushansky K
    Annu Rev Med; 1997; 48():1-11. PubMed ID: 9046940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro.
    Wun T; Paglieroni T; Hammond WP; Kaushansky K; Foster DC
    Am J Hematol; 1997 Mar; 54(3):225-32. PubMed ID: 9067502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of thrombopoietin on clinical practice.
    Basser R
    Curr Pharm Des; 2002; 8(5):369-77. PubMed ID: 12069375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth factors and their impact on transfusion medicine.
    Miller YM; Klein HG
    Vox Sang; 1996; 71(4):196-204. PubMed ID: 8958642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of automated plateletpheresis on systemic levels of hematopoietic growth factors.
    Weisbach V; Friedlein H; Glaser A; Zingsem J; Zimmermann R; Eckstein R
    Transfusion; 1999 Aug; 39(8):889-94. PubMed ID: 10504126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reticulated platelets as a marker of megakaryopoiesis in liver cirrhosis; relation to thrombopoietin and hepatocyte growth factor serum concentration.
    Panasiuk A; Prokopowicz D; Zak J; Panasiuk B
    Hepatogastroenterology; 2004; 51(58):1124-8. PubMed ID: 15239259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
    Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
    Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing a co-culture system for effective megakaryo/thrombopoiesis from umbilical cord blood hematopoietic stem/progenitor cells.
    Hatami J; Andrade PZ; Alves de Matos AP; Djokovic D; Lilaia C; Ferreira FC; Cabral JM; da Silva CL
    Cytotherapy; 2015 Apr; 17(4):428-42. PubMed ID: 25680300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production.
    Abraham M; Weiss ID; Wald H; Wald O; Nagler A; Beider K; Eizenberg O; Peled A
    Br J Haematol; 2013 Oct; 163(2):248-59. PubMed ID: 23906028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin.
    Kaushansky K
    N Engl J Med; 1998 Sep; 339(11):746-54. PubMed ID: 9731092
    [No Abstract]   [Full Text] [Related]  

  • 19. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
    Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells.
    Neelis KJ; Dubbelman YD; Qingliang L; Thomas GR; Eaton DL; Wagemaker G
    Exp Hematol; 1997 Sep; 25(10):1084-93. PubMed ID: 9293906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.